| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Andrology, Vol 15, Issue 3 212-215, Copyright © 1994 by The American Society of Andrology
JOURNAL ARTICLE |
L. J. Gooren
Division of Andrology, Free University Hospital Amsterdam, The Netherlands.
Testosterone undecanoate (Andriol) is an oral androgen that provides the hypogonadal patient with the unmodified testosterone molecule. It was introduced in the mid-1970s. This is a report on the safety of this oral androgen. Of 35 men originally included in the study, 33 could be followed up for a minimum of 10 years. In them no alteration in the biochemical parameters of liver function could be detected. Upon annual measurements (7-9 hours after ingestion of testosterone undecanoate), serum levels of testosterone ranged between 5.4 +/- 1.9 and 6.5 +/- 1.9 nmol/L (normal range 8-24) and of 5 alpha-dihydrotestosterone between 3.2 +/- 1.8 and 3.5 +/- 1.7 nmol/L (normal range 0.8-2.5). These levels remained constant during the study period, indicating that there is no increased hepatic enzymatic breakdown of the androgen over time. Eight men were older than 50 years at the start of the study. Over the 10-year period in two of them a mild reduction in urine flow was measured, whereas in the other six this could not be demonstrated. Digital examination of the prostate did not reveal signs of prostate tumors. Testosterone undecanoate appears to be a safe oral androgen. A yearly checkup of the patient on therapy with this androgen seems adequate.
This article has been cited by other articles:
 |
|
 |
|
  J. K. Amory, S. T. Page, and W. J. Bremner Oral Testosterone in Oil: Pharmacokinetic Effects of 5{alpha} Reduction by Finasteride or Dutasteride and Food Intake in Men J Androl, January 1, 2006; 27(1): 72 - 78. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Amory and W. J. Bremner Oral Testosterone in Oil Plus Dutasteride in Men: A Pharmacokinetic Study J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2610 - 2617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Wang, R. Swerdloff, M. Kipnes, A. M. Matsumoto, A. S. Dobs, G. Cunningham, L. Katznelson, T. J. Weber, T. C. Friedman, P. Snyder, et al. New Testosterone Buccal System (Striant) Delivers Physiological Testosterone Levels: Pharmacokinetics Study in Hypogonadal Men J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3821 - 3829. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Korbonits, M. Slawik, D. Cullen, R. J. Ross, G. Stalla, H. Schneider, M. Reincke, P. M. Bouloux, and A. B. Grossman A Comparison of a Novel Testosterone Bioadhesive Buccal System, Striant, with a Testosterone Adhesive Patch in Hypogonadal Males J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2039 - 2043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Amory, G. K. E. Scriba, D. W. Amory, and W. J. Bremner Oral Testosterone-Triglyceride Conjugate in Rabbits: Single-Dose Pharmacokinetics and Comparison With Oral Testosterone Undecanoate J Androl, September 1, 2003; 24(5): 716 - 720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Shackleford, W. A. Faassen, N. Houwing, H. Lass, G. A. Edwards, C. J. H. Porter, and W. N. Charman Contribution of Lymphatically Transported Testosterone Undecanoate to the Systemic Exposure of Testosterone after Oral Administration of Two Andriol Formulations in Conscious Lymph Duct-Cannulated Dogs J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 925 - 933. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bhasin, A. B. Singh, R. P. Mac, B. Carter, M. I. Lee, and G. R. Cunningham Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan J Androl, May 1, 2003; 24(3): 299 - 311. [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Morley and H. M. Perry III Androgens and Women at the Menopause and Beyond J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2003; 58(5): M409 - 416. [Full Text] [PDF]
|
|
|
|
|
|
R. E. Gerstenbluth, P. N. Maniam, E. W. Corty, and A. D. Seftel Prostate-Specific Antigen Changes in Hypogonadal Men Treated With Testosterone Replacement J Androl, November 1, 2002; 23(6): 922 - 926. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. von Eckardstein and E. Nieschlag Treatment of Male Hypogonadism With Testosterone Undecanoate Injected at Extended Intervals of 12 Weeks: A Phase II Study J Androl, May 1, 2002; 23(3): 419 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Matsumoto Andropause: Clinical Implications of the Decline in Serum Testosterone Levels With Aging in Men J. Gerontol. A Biol. Sci. Med. Sci., February 1, 2002; 57(2): M76 - 99. [Full Text]
|
|
|
|
|
|
A. Vermeulen Androgen Replacement Therapy in the Aging Male--A Critical Evaluation J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2380 - 2390. [Full Text] [PDF]
|
|
|
|
|
|
G.-y. Zhang, Y.-q. Gu, X.-h. Wang, Y.-g. Cui, and W. J. Bremner A Clinical Trial of Injectable Testosterone Undecanoate as a Potential Male Contraceptive in Normal Chinese Men J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3642 - 3647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Winters Current Status of Testosterone Replacement Therapy in Men Arch Fam Med, May 1, 1999; 8(3): 257 - 263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. S. Drop, W. J. de Waal, and S. M. P. F. de Muinck Keizer-Schrama Sex Steroid Treatment of Constitutionally Tall Stature Endocr. Rev., October 1, 1998; 19(5): 540 - 558. [Abstract] [Full Text]
|
|
|
|
|
|
S. Bhasin and W. J. Bremner Emerging Issues in Androgen Replacement Therapy J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 3 - 8. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
